Zymeworks Inc.
$26.24
$0.19 (+0.73%)
$25.91Day Range$26.55
Key Statistics
Market Cap
$1.86B
Shares Outstanding
71.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 28, 2017
Round Lot
100
Locale
US
Trading Data
Day Open
$26.17
Day High
$26.55
Day Low
$25.91
Volume
687.0K
VWAP
$26.12
Prev Close
$26.05
Transactions
--
Acc. Volume
--
About Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
PHARMACEUTICAL PREPARATIONSSIC 2834264 employees108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709302-274-8744IPO Apr 28, 2017US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001937653
- Composite FIGI
- BBG019XSYC89
- Share Class FIGI
- BBG019XSYC98
- Ticker Root
- ZYME
- SIC Code
- 2834
About Zymeworks Inc. (ZYME) Stock
Zymeworks Inc. (ZYME) closed the 2026-09-16 session at $26.24, up 0.73% versus the previous close (+0.19). The stock opened at $26.17 and traded between $25.91 and $26.55 during that session. Session trading volume was 687K shares. The volume-weighted average price (VWAP) is $26.12.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks Inc. has a market capitalization of $1.86 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ZYME is listed on the XNAS exchange. The company employs approximately 264 people. Zymeworks Inc. is headquartered in MIDDLETOWN, DE. The recorded listing date is 2017-04-28.
On this page you can find market ZYME stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.